Elsevier

The Lancet Oncology

Volume 11, Issue 8, August 2010, Pages 711-712
The Lancet Oncology

Reflection and Reaction
How can we tell if PET imaging for cancer is cost effective?

https://doi.org/10.1016/S1470-2045(10)70164-9Get rights and content

References (10)

  • H van Tinteren et al.

    Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial

    Lancet

    (2002)
  • GJ Herder et al.

    Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study

    J Clin Oncol

    (2006)
  • DE Maziak et al.

    Positron emission tomography in staging early lung cancer: a randomized trial

    Ann Intern Med

    (2009)
  • B Fischer et al.

    Preoperative staging of lung cancer with combined PET-CT

    N Engl J Med

    (2009)
  • RC Viney et al.

    Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer

    J Clin Oncol

    (2004)
There are more references available in the full text version of this article.

Cited by (9)

  • The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival data

    2013, Radiotherapy and Oncology
    Citation Excerpt :

    These patients were equally represented in the palliative and curative groups in the study and they were included in our previous report [30] that showed rapid increases in tumour volume and frequent stage migration occurring between serial PET/CT scans in untreated NSCLC patients. Use of a contemporaneous dedicated PET/CT scan for staging and RT planning is highly likely to be cost effective in NSCLC [31]. In this series, the survival of the entire group comprising both radical and palliative patients compared favourably with historical results of chemoRT in NSCLC, despite the fact that only two thirds of patients actually received this expensive and toxic therapy.

  • Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer

    2011, Clinical Radiology
    Citation Excerpt :

    In the present study, 7% (7/102) of patients had a change in the surgical approach or a second operation as a direct consequence of PET-CT, which is similar to previously published data (7–10%).24,26 Recently, there has been increasing emphasis on the cost-effectiveness of FDG PET-CT in a variety of oncological settings.27,28 Using different methods, cost-effectiveness of PET has been demonstrated for several tumour types and indications, including staging of non-small cell lung cancer, characterization of solitary pulmonary nodules, staging of head and neck cancer, pancreatic cancer staging, and staging of lymphoma.29–34

  • Delivering affordable cancer care in high-income countries

    2011, The Lancet Oncology
    Citation Excerpt :

    Thus, multimodal imaging is becoming a focus for the medical community and those responsible for funding health care. On one hand, the attractions of earlier and more accurate diagnosis are obvious to clinicians and dominate their perspectives.195 On the other hand, governments and health-insurance companies are concerned by the growing cost of health care and are worried by the high potential cost of ever more expensive imaging technologies.

View all citing articles on Scopus
View full text